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through June 2009) for 32,338 patients aged40 years prescribed ipratropium (IPR)
(N10,617) or tiotropium (TIO) (N9,126) in comparison to fluticasone propionate/
salmeterol combination (FSC) (N12,595). Patients initiating with IPR (and sepa-
rately, TIO) werematched to patients initiating with FSC based on propensity to be
prescribed IPR (separately, TIO), considering demographics, comorbidities and uti-
lization characteristics assessed during 6 months before first IMT claim. RESULTS:
Percentage of each group propensitymatched to FSCwas 80.2%, IPR and 89.1%, TIO.
ORs (95% confidence intervals (CI)) for IPR vs. FSC were: ED - PM 1.86 (1.64-2.10), MR
1.81 (1.57-2.08); Hospitalization – PM 1.47 (1.27-1.70), MR 1.53 (1.35-1.75); ED/Hospi-
talization PM 1.67 (1.50-1.85), MR 1.72 (1.56-1.90). For TIO versus FSC, ORs (95% CI)
were: ED - PM 1.34 (1.14-1.47), MR 1.34 (1.17-1.54); Hospitalization – PM 1.10 (0.94-
1.28), MR 1.19 (1.04-1.37); ED/Hospitalization PM 1.21 (1.07, 1.36), MR 1.28 (1.15, 1.42).
IRRs reflected similar differences between themethods. Compared to FSC patients,
total COPD-related health care costs were higher for IPR (PM&MR, P0.01) and TIO
(PM P0.05, MR P0.01). CONCLUSIONS: The MR and PM methods of adjusting for
baseline differences between treatment populations produce similar results.
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OBJECTIVES: The significant burden of uncontrolled asthma can be translated into
substantial direct and indirect costs to the US health care system. The objectives of
the Characterization of Allergic Asthma: A Chart Review In Moderate-To-Severe
Disease To Assess Asthma Control, Allergies, Patient Outcomes And Treatment
Study (CHARIOT) study were to assess control of patients withmoderate-to-severe
asthma, examine the natural history of disease, practice patterns and resource
utilization in specialty community practices according to recent National Asthma
Education and Prevention Program guidelines by using a novel online approach to
gathering data and quickly demonstrating results. METHODS: This was a retro-
spective, multicenter, randomized study of 1009 patient charts in 60 US allergy and
pulmonology community practices. Assessment of patient control, the primary
endpoint, was achieved by analyzing data entered via internet-based or paper case
report forms (CRFs) Uncontrolled asthma was defined by occurrence of any of the
events in the recent 12 months of continuous follow-up: systemic corticosteroid
burst; frequent short-acting 2 agonist use; ER visit; asthma exacerbation (hospi-
talization and/or unscheduled visit; limitations on activities; decline in lung func-
tion to80% predicted FEV1 or PEF); daytime dyspnea; doubling of inhaled cortico-
steroid dose; or addition of another controller medication. RESULTS: A total of 114
sites were invited to participate in CHARIOT, with a 63% response rate leading to
site enrollment. Sixty investigator sites participated to completion and, after We-
bEx training, only 1 requested paper CRFs but later elected to use electronic forms.
Data was successfully collected and analyzed within a 3-month period. Of the 365
male and 644 female patients enrolled (mean 43.2 17.1 years), 81.9%were deemed
to be uncontrolled. CONCLUSIONS: Greater than 80% of asthma patients from
specialty practices were uncontrolled with regard to asthma symptoms. The novel
internet technology allowed for efficient data collection frommultiple sites within
a short time frame.
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OBJECTIVES: Smoking cessation models have typically evaluated the impact of a
single quit attempt on long term outcomes in smokers but smoking cessation is
characterized bymultiple quit attempts. A DES was developed to simulate lifetime
smoking patterns and the impact on smoking-related complications and costs.
This study evaluates the effect on predictions when modeling single versus mul-
tiple quit attempts.METHODS: Using data from trials, surveys, and the literature,
the DES simulates individuals’ lifetime smoking behaviors and their impact on
outcomes. The simulation assigns and reassigns the initial outcomes of each quit
attempt, time between quit attempts, relapses, and interventions used in each
attempt (varenicline, bupropion, nicotine replacement, behavioral modification,
unassisted). Comorbidities include myocardial infarction, stroke, COPD, and lung
cancer. Market survey data are used to assign the initial intervention for quit at-
tempts. Only direct costs (2010 $US) are considered. All outcomes are discounted at
3%/year. RESULTS:When analyses are restricted to a single quit attempt, mean life
expectancy in the population is 15.8 years, and QALYs 13.2; the lifetime costs of
treatment and smoking related comorbidities average $55,925. Allowing for multi-
ple quit attempts (average 7.6 attempts/smoker) increases the average time indi-
viduals spend abstinent by 8.8 years. Consequently, predicted life expectancy in-
creases by 1.1 years; QALYs by 0.9. Despite increased smoking intervention costs,
total lifetime costs fall by $3300/smoker. Analyses comparing initial varenicline
treatment to mixed initial treatments and allowing multiple versus single quit
attempts reduces varenicline-related predicted health gains and cost offsets, al-
though both groups have better outcomes with multiple quit attempts. The reduc-
tion is apparent because individuals initially on less effective treatments are able to
quit smoking in subsequent attempts. Nevertheless, varenicline is dominant or
highly cost-effective in both scenarios. CONCLUSIONS: Allowing multiple rather
than single quit attempts in simulating outcomes for smokers provides better in-
formation for decision making.
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OBJECTIVES: Providing participants with choices in how their data are collected
may lead to greater participation, less missing data, improved data quality, and in
some cases, decreased costs in data collection. To facilitate combining data from
multiple versions, the goals of this study were to provide recommended steps to
assess measurement comparability using a crossover study design and a case-
finding questionnaire, the Lung Function Questionnaire (LFQ), as an example.
METHODS: In the study, the LFQ was administered to participants via paper, Web,
interactive voice response system, and interview. A randomized crossover design
was used to gather data across themultiple administration types. In addition to the
LFQ, participants completed demographic and health questions, and a short ques-
tionnaire regarding their administration preference. Four recommended evalua-
tion steps are described and illustrated using data from the crossover study: 1)
comparisons of the item-level responses and agreement; 2) comparison of mean
scale scores; 3) classification of scores; and 4) questions designed to collect usability
and administration preference. RESULTS: In this example, item-level kappa statis-
tics between the paper and the alternate versions ranged from good to excellent,
intraclass correlation coefficients for mean scores were above 0.70, and the rate of
disagreement ranged from 2% to 14%. In addition, although participants had an
administration preference, they reported few difficulties with the versions they
were assigned. CONCLUSIONS: The steps described provide a guide for evaluating
whether to combine scores across administration versions to simplify analyses and
interpretation under a crossover design. The guide recommends the investigation
of item-level responses, summary scores, and participant usability/preference
when comparing versions. Each of these steps provides unique information to
support a comprehensive evaluation and informed decisions regarding whether to
combine data. Results of this particular study for each of the evaluation steps
supported the use of multiple modes of the LFQ.
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OBJECTIVES: Comorbidities are conditions or diseases besides the one of primary
interest. A comorbidity index condenses all the coexistent conditions to a single
score and comorbidity indexes have been extensively used to adjust analyses for
the impact of comorbidities. De Groot and colleagues published a literature review
in 2003 listing available indexes and reporting their validity.The objective of this
study was to review published methods to measure comorbidity and thereby pro-
vide an update of the publication by de Groot and colleagues.METHODS: A struc-
tured search, using as primary search terms comorbidity, multimorbidity, and co-
existing disease, was undertaken in Embase.com to identify studies published
since 2000 in which an index to measure comorbidity is described. For validity,
correlation coefficients, ratios, explained variance, and the area under the receiver
operating characteristic curve were used. Regression models predicting future
events that were significant or significantly improved after adding comorbidity as
a covariatewas considered to support validity. Parameters used to assess reliability
were among others correlation coefficients. RESULTS: Sixtyfour publications were
studied resulting in twentyfive different indexes, to measure comorbidity were
identified, compared to the thirteen identified by de Groot and colleagues (2003). In
line with previous findings, the Charlson Comorbidity Index (CCI) generated the
greatest number of studies and the most consistent results regarding validity and
reliability. CCI compiles the weighted mortality association of nineteen different
diseases with a number of adaptations for specific circumstances. CONCLUSIONS:
The main finding is that the CCI remains the most used and validated index, and
also a number of new comorbidity indexes have been identified in this study.
Assessment of comorbidity is an area of interest for both health economists and
epidemiologists and it seems to be receiving increased attention.
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OBJECTIVES: To introduce amethod that combines the propensity score matching
and interrupted time-series models to measure drug therapy guidelines on
outcomes.METHODS: Propensity score matching is used to balance groups before
the trend is analyzed. The “kitchen sink” approach is used for propensity score
matching. Interrupted time-series models are applied over the matched sample.
The time-series model contains two predictor variables: the binary intervention
variable and an interval coding for time. This model controls for the confounding
influence of any underlying trend and ensures that any estimated change in the
mean level of the series after intervention is not simply due to the fact that the
series was already decreasing or increasing. RESULTS: To illustrate the model,
changes in the utilization of two hypothetical drugs were analyzed after issuance
of guidelines. Patients who used these two drugs were different at the baseline in
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